Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 62-72

  Taner, Sabrina B ^a,b   Pando, Marcelo J ^a,b,c   Roberts, Allison ^a   Schellekens, Jennifer ^d   Marsh, Steven G E ^d,e   Malmberg, Karl Johan ^f   Parham, Peter ^c   Brodsky, Frances M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; EPITOPE; GAMMA INTERFERON; HLA B ANTIGEN; LYMPHOCYTE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR KIR3DL1 002; NATURAL KILLER CELL RECEPTOR KIR3DL1 004; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL SURFACE; CONFORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOPLASMIC RETICULUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MEMBRANE TRANSPORT; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CALRETICULIN; CELL LINE; ENDOPLASMIC RETICULUM; HLA-B ANTIGENS; HUMANS; INTRACELLULAR FLUID; KILLER CELLS, NATURAL; LIGANDS; MOLECULAR CHAPERONES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN TRANSPORT; PROTEIN UNFOLDING; RECEPTORS, KIR3DL1; STRESS, PHYSIOLOGICAL;

EID: 79251551640     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903657     Document Type: Article

References (75)

1. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112: 461-469.
2. Cooper, M. A., M. Colonna, and W. M. Yokoyama. 2009. Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep. 10: 1103-1110.
3. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
4. Long, E. O. 2008. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol. Rev. 224: 70-84.
5. Yawata, M., N. Yawata, M. Draghi, F. Partheniou, A. M. Little, and P. Parham. 2008. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112: 2369-2380.
6. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342.
7. Shilling, H. G., L. A. Guethlein, N. W. Cheng, C. M. Gardiner, R. Rodriguez, D. Tyan, and P. Parham. 2002. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J. Immunol. 168: 2307-2315.
8. Khakoo, S. I., and M. Carrington. 2006. KIR and disease: a model system or system of models? Immunol. Rev. 214: 186-201. (Pubitemid 44707911)
9. Rajagopalan, S., and E. O. Long. 2005. Understanding how combinations of HLA and KIR genes influence disease. J. Exp. Med. 201: 1025-1029.
10. Moffett, A., and C. Loke. 2006. Immunology of placentation in eutherian mammals. Nat. Rev. Immunol. 6: 584-594.
11. Velardi, A. 2008. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr. Opin. Immunol. 20: 581-587.
12. Gendzekhadze, K., P. J. Norman, L. Abi-Rached, T. Graef, A. K. Moesta, Z. Layrisse, and P. Parham. 2009. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc. Natl. Acad. Sci. USA 106: 18692-18697.
13. Vilches, C., and P. Parham. 2002. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20: 217-251.
14. Carrington, M., M. P. Martin, and J. van Bergen. 2008. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16: 620-627.
15. Robinson, J., K. Mistry, H. McWilliam, R. Lopez, and S. G. Marsh. 2010. IPD - the Immuno Polymorphism Database. Nucleic Acids Res. 38: D863-D869.
16. Norman, P. J., L. Abi-Rached, K. Gendzekhadze, D. Korbel, M. Gleimer, D. Rowley, D. Bruno, C. V. Carrington, D. Chandanayingyong, Y. H. Chang, et al. 2007. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat. Genet. 39: 1092-1099.
17. Gumperz, J. E., V. Litwin, J. H. Phillips, L. L. Lanier, and P. Parham. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181: 1133-1144.
18. Cella, M., A. Longo, G. B. Ferrara, J. L. Strominger, and M. Colonna. 1994. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J. Exp. Med. 180: 1235-1242.
19. Gardiner, C. M., L. A. Guethlein, H. G. Shilling, M. Pando, W. H. Carr, R. Rajalingam, C. Vilches, and P. Parham. 2001. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166: 2992-3001.
20. Thomas, R., E. Yamada, G. Alter, M. P. Martin, A. A. Bashirova, P. J. Norman, M. Altfeld, P. Parham, S. K. Anderson, D.W. McVicar, and M. Carrington. 2008. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J. Immunol. 180: 6743-6750.
21. Carr, W. H., M. J. Pando, and P. Parham. 2005. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 175: 5222-5229.
22. Yawata, M., N. Yawata, M. Draghi, A. M. Little, F. Partheniou, and P. Parham. 2006. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203: 633-645.
23. O'Connor, G. M., K. J. Guinan, R. T. Cunningham, D. Middleton, P. Parham, and C. M. Gardiner. 2007. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178: 235-241.
24. Thananchai, H., G. Gillespie, M. P. Martin, A. Bashirova, N. Yawata, M. Yawata, P. Easterbrook, D. W. McVicar, K. Maenaka, P. Parham, et al. 2007. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178: 33-37. (Pubitemid 46033585)
25. Alter, G., and M. Altfeld. 2009. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J. Intern. Med. 265: 29-42.
26. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. Brown, W. L. Shupert, J. Phair, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39: 733-740.
27. Pando, M. J., C. M. Gardiner, M. Gleimer, K. L. McQueen, and P. Parham. 2003. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J. Immunol. 171: 6640-6649.
28. Sharma, D., K. Bastard, L. A. Guethlein, P. J. Norman, N. Yawata, M. Yawata, M. Pando, H. Thananchai, T. Dong, S. Rowland-Jones, et al. 2009. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402. J. Immunol. 183: 4569-4582.
29. Rajagopalan, S., Y. T. Bryceson, S. P. Kuppusamy, D. E. Geraghty, A. van der Meer, I. Joosten, and E. O. Long. 2006. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 4: e9.
30. Masilamani, M., G. Peruzzi, F. Borrego, and J. E. Coligan. 2009. Endocytosis and intracellular trafficking of human natural killer cell receptors. Traffic 10: 1735-1744.
31. Wu, J., H. Cherwinski, T. Spies, J. H. Phillips, and L. L. Lanier. 2000. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J. Exp. Med. 192: 1059-1068.
32. Lanier, L. L., B. Corliss, J. Wu, and J. H. Phillips. 1998. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8: 693-701.
33. Carr, W. H., D. B. Rosen, H. Arase, D. F. Nixon, J. Michaelsson, and L. L. Lanier. 2007. Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J. Immunol. 178: 647-651.
34. Trundley, A., H. Frebel, D. Jones, C. Chang, and J. Trowsdale. 2007. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur. J. Immunol. 37: 780-787.
35. Orr, M. T., J. C. Sun, D. G. Hesslein, H. Arase, J. H. Phillips, T. Takai, and L. L. Lanier. 2009. Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection. J. Exp. Med. 206: 807-817.
36. Tassi, I., G. Le Friec, S. Gilfillan, T. Takai, W. M. Yokoyama, and M. Colonna. 2009. DAP10 associates with Ly49 receptors but contributes minimally to their expression and function in vivo. Eur. J. Immunol. 39: 1129-1135.
37. Held, W., and R. A. Mariuzza. 2008. Cis interactions of immunoreceptors with MHC and non-MHC ligands. Nat. Rev. Immunol. 8: 269-278.
38. Robertson, M. J., K. J. Cochran, C. Cameron, J. M. Le, R. Tantravahi, and J. Ritz. 1996. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24: 406-415.
39. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31: 429-434.
40. Vilches, C., J. Castaño, N. Gómez-Lozano, and E. Estefanía. 2007. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 70: 415-422.
41. Belle, I., L. Hou, M. Chen, N. K. Steiner, J. Ng, and C. K. Hurley. 2008. Investigation of killer cell immunoglobulin-like receptor gene diversity in KIR3DL1 and KIR3DS1 in a transplant population. Tissue Antigens 71: 434-439.
42. Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and A. Ziegler. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14: 9-20.
43. Soldà, T., S. Olivari, and M. Molinari. 2005. Analyzing folding and degradation of metabolically labelled polypeptides by conventional and diagonal sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biol. Proced. Online 7: 136-143.
44. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
45. Stam, N. J., H. Spits, and H. L. Ploegh. 1986. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol. 137: 2299-2306.
46. McCann, F. E., B. Vanherberghen, K. Eleme, L. M. Carlin, R. J. Newsam, D. Goulding, and D. M. Davis. 2003. The size of the synaptic cleft and distinct distributions of filamentous actin, ezrin, CD43, and CD45 at activating and inhibitory human NK cell immune synapses. J. Immunol. 170: 2862-2870.
47. Ljunggren, H. G., N. J. Stam, C. Ohlén, J. J. Neefjes, P. Höglund, M. T. Heemels, J. Bastin, T. N. Schumacher, A. Townsend, K. Kärre, et al. 1990. Empty MHC class I molecules come out in the cold. Nature 346: 476-480.
48. Griffiths, G., S. Pfeiffer, K. Simons, and K. Matlin. 1985. Exit of newly synthesized membrane proteins from the trans cisterna of the Golgi complex to the plasma membrane. J. Cell Biol. 101: 949-964.
49. Saraste, J., and E. Kuismanen. 1984. Pre- and post-Golgi vacuoles operate in the transport of Semliki Forest virus membrane glycoproteins to the cell surface. Cell 38: 535-549.
50. Matlin, K. S., and K. Simons. 1983. Reduced temperature prevents transfer of a membrane glycoprotein to the cell surface but does not prevent terminal glycosylation. Cell 34: 233-243.
51. Hebert, D. N., J. X. Zhang, W. Chen, B. Foellmer, and A. Helenius. 1997. The number and location of glycans on influenza hemagglutinin determine folding and association with calnexin and calreticulin. J. Cell Biol. 139: 613-623.
52. Danilczyk, U. G., M. F. Cohen-Doyle, and D. B. Williams. 2000. Functional relationship between calreticulin, calnexin, and the endoplasmic reticulum luminal domain of calnexin. J. Biol. Chem. 275: 13089-13097.
53. Pieren, M., C. Galli, A. Denzel, and M. Molinari. 2005. The use of calnexin and calreticulin by cellular and viral glycoproteins. J. Biol. Chem. 280: 28265-28271.
54. Abrami, L., B. Kunz, I. Iacovache, and F. G. van der Goot. 2008. Palmitoylation and ubiquitination regulate exit of the Wnt signaling protein LRP6 from the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA 105: 5384-5389.
55. Ron, D., and P. Walter. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8: 519-529.
56. Yoshida, H., T. Matsui, A. Yamamoto, T. Okada, and K. Mori. 2001. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 107: 881-891.
57. Calfon, M., H. Zeng, F. Urano, J. H. Till, S. R. Hubbard, H. P. Harding, S. G. Clark, and D. Ron. 2002. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415: 92-96.
58. Sanjanwala, B., M. Draghi, P. J. Norman, L. A. Guethlein, and P. Parham. 2008. Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1. J. Immunol. 181: 6293-6300.
59. Parham, P., B. N. Alpert, H. T. Orr, and J. L. Strominger. 1977. Carbohydrate moiety of HLA antigens. Antigenic properties and amino acid sequences around the site of glycosylation. J. Biol. Chem. 252: 7555-7567.
60. Komatsu, F., and M. Kajiwara. 1998. Enhancement of tumor cell lysis by natural killer cells after blocking of HLA-monomorphic determinant using F(ab')2 fragment of W6/32. Cancer Detect. Prev. 22: 168-175.
61. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22. (Pubitemid 39626587)
62. Halfpenny, I. A., D. Middleton, Y. A. Barnett, and F. Williams. 2004. Investigation of killer cell immunoglobulin-like receptor gene diversity: IV. KIR3DL1/S1. Hum. Immunol. 65: 602-612.
63. Morvan, M., C. Willem, K. Gagne, N. Kerdudou, G. David, V. Sébille, G. Folléa, J. D. Bignon, and C. Retière. 2009. Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK cells. J. Immunol. 182: 6727-6735.
64. Schaefer, M. R., M. Williams, D. A. Kulpa, P. K. Blakely, A. Q. Yaffee, and K. L. Collins. 2008. A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. J. Immunol. 180: 7804-7817.
65. Borrego, F., J. Kabat, T. B. Sanni, and J. E. Coligan. 2002. NK cell CD94/ NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes. J. Immunol. 169: 6102-6111.
66. Masilamani, M., S. Narayanan, M. Prieto, F. Borrego, and J. E. Coligan. 2008. Uncommon endocytic and trafficking pathway of the natural killer cell CD94/ NKG2A inhibitory receptor. Traffic 9: 1019-1034.
67. Snyder, M. R., T. Nakajima, P. J. Leibson, C. M. Weyand, and J. J. Goronzy. 2004. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J. Immunol. 173: 3725-3731.
68. Bléry, M., J. Delon, A. Trautmann, A. Cambiaggi, L. Olcese, R. Biassoni, L. Moretta, P. Chavrier, A. Moretta, M. Daëron, and E. Vivier. 1997. Reconstituted killer cell inhibitory receptors for major histocompatibility complex class I molecules control mast cell activation induced via immunoreceptor tyrosine-based activation motifs. J. Biol. Chem. 272: 8989-8996.
69. Steiner, N. K., S. Dakshanamurthy, C. J. VandenBussche, and C. K. Hurley. 2008. Extracellular domain alterations impact surface expression of stimulatory natural killer cell receptor KIR2DS5. Immunogenetics 60: 655-667.
70. Rojo, S., N. Wagtmann, and E. O. Long. 1997. Binding of a soluble p70 killer cell inhibitory receptor to HLA-B*5101: requirement for all three p70 immunoglobulin domains. Eur. J. Immunol. 27: 568-571.
71. Khakoo, S. I., R. Geller, S. Shin, J. A. Jenkins, and P. Parham. 2002. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J. Exp. Med. 196: 911-921.
72. VandenBussche, C. J., S. Dakshanamurthy, P. E. Posch, and C. K. Hurley. 2006. A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain. J. Immunol. 177: 5347-5357.
73. VandenBussche, C. J., T. J. Mulrooney, W. R. Frazier, S. Dakshanamurthy, and C. K. Hurley. 2009. Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun. 10: 162-173.
74. Doucey, M. A., L. Scarpellino, J. Zimmer, P. Guillaume, I. F. Luescher, C. Bron, and W. Held. 2004. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat. Immunol. 5: 328-336.
75. Scarpellino, L., F. Oeschger, P. Guillaume, J. D. Coudert, F. Lévy, G. Leclercq, and W. Held. 2007. Interactions of Ly49 family receptors with MHC class I ligands in trans and cis. J. Immunol. 178: 1277-1284.